| 1. | Renal angiomyolipoma (AML) harboring a missense mutation of TSC2 with copy-neutral loss of heterozygosity (CN-LOH). |
| Idogawa M, Hida T, Tanaka T, Ohira N, Tange S, Sasaki Y, Uhara H, Masumori N, Tokino T, Natori H. | |
| Cancer Biol Ther. 2019 Dec 17:1-5. doi: 10.1080/15384047.2019.1702406. [Epub ahead of print] | |
| PMID: 31847710 [PubMed - as supplied by publisher] | |
| Similar articles |
| 2. | p53-induced ARVCF modulates the splicing landscape and supports the tumor suppressive function of p53. |
| Suzuki N, Idogawa M, Tange S, Ohashi T, Sasaki Y, Nakase H, Tokino T. | |
| Oncogene. 2019 Dec 11. doi: 10.1038/s41388-019-1133-7. [Epub ahead of print] | |
| PMID: 31827232 [PubMed - as supplied by publisher] | |
| Similar articles |
| 3. | Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer. |
| Idogawa M, Nakase H, Sasaki Y, Tokino T. | |
| J Oncol. 2019 May 2;2019:4368068. doi: 10.1155/2019/4368068. eCollection 2019. Erratum in: J Oncol. 2019 Aug 7;2019:4757046. | |
| PMID: 31186635 [PubMed] Free PMC Article | |
| Similar articles |
| 4. | Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients. |
| Ogi K, Kobayashi J, Nakagaki T, Okamoto J, Koike K, Hirokawa N, Someya M, Sakamoto H, Takada K, Tokino T, Sasaki Y, Hiratsuka H, Miyazaki A. | |
| Oral Oncol. 2019 Dec 12:104509. doi: 10.1016/j.oraloncology.2019.104509. [Epub ahead of print] No abstract available. | |
| PMID: 31839407 [PubMed - as supplied by publisher] | |
| Similar articles |
| 5. | Genomic characterization for familial cases with urothelial carcinoma. |
| Shindo T, Hirobe M, Adachi Y, Sasaki Y, Tokino T, Masumori N. | |
| Int Cancer Conf J. 2019 Jun 27;8(4):185-189. doi: 10.1007/s13691-019-00381-7. eCollection 2019 Oct. | |
| PMID: 31559120 [PubMed] | |
| Similar articles |
| 6. | FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. |
| Darwis NDM, Nachankar A, Sasaki Y, Matsui T, Noda SE, Murata K, Tamaki T, Ando K, Okonogi N, Shiba S, Irie D, Kaminuma T, Kumazawa T, Anakura M, Yamashita S, Hirakawa T, Kakoti S, Hirota Y, Tokino T, Iwase A, Ohno T, Shibata A, Oike T, Nakano T. | |
| Int J Mol Sci. 2019 Sep 14;20(18). pii: E4563. doi: 10.3390/ijms20184563. | |
| PMID: 31540114 [PubMed - indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| 7. | UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. |
| Niinuma T, Kitajima H, Kai M, Yamamoto E, Yorozu A, Ishiguro K, Sasaki H, Sudo G, Toyota M, Hatahira T, Maruyama R, Tokino T, Nakase H, Sugai T, Suzuki H. | |
| Clin Epigenetics. 2019 May 7;11(1):70. doi: 10.1186/s13148-019-0668-3. | |
| PMID: 31064417 [PubMed - in process] Free PMC Article | |
| Similar articles |
| 8. | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. |
| Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S. | |
| J Exp Clin Cancer Res. 2019 Mar 12;38(1):127. doi: 10.1186/s13046-019-1121-3. | |
| PMID: 30866995 [PubMed - indexed for MEDLINE] Free PMC Article | |
| Similar articles |
| 9. | DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. |
| Ishiguro K, Kitajima H, Niinuma T, Ishida T, Maruyama R, Ikeda H, Hayashi T, Sasaki H, Wakasugi H, Nishiyama K, Shindo T, Yamamoto E, Kai M, Sasaki Y, Tokino T, Nakase H, Suzuki H. | |
| Haematologica. 2019 Jan;104(1):155-165. doi: 10.3324/haematol.2018.191262. Epub 2018 Aug 31. | |
| PMID: 30171029 [PubMed - in process] Free PMC Article | |
| Similar articles |